GLP-1 Receptor Agonist
44 drugs across 9 manufacturers|10 Generic,34 Brand
The GLP-1 Receptor Agonist class contains 44 NDCs from 9 manufacturers (10 generic, 34 brand), at an average NADAC of $324.74 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
44
10G / 34B
Manufacturers
9
Avg $324.7404/unit
Avg 7d Change
-0.80%
Across 37 drugs with changes
7d Activity
of 44 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
9 manufacturers producing drugs in this therapeutic class
Follow this class across the site
These links connect the therapeutic class page to the specific suppliers, markets, and trend surfaces that help users keep exploring.
Top supplier
Eli Lilly and Company manufacturer profile
Review the supplier with the strongest product footprint inside this therapeutic class.
Lead market
tirzepatide market page
Move from the therapeutic class into the molecule that appears most often in this class-specific portfolio.
Trend hub
Latest trend hub
Compare this class against the rest of the weekly NADAC trend surface.
Guide
Understanding NADAC pricing
Use the explainer when you need a plain-English refresher on how these class-level numbers are published and interpreted.
Frequently Asked Questions
How many drugs are in the GLP-1 Receptor Agonist class?
The GLP-1 Receptor Agonist class contains 44 NDCs from 9 manufacturers — 10 generic and 34 brand products.
What is the average price of GLP-1 Receptor Agonist drugs?
The average NADAC for the GLP-1 Receptor Agonist class is $324.7404 per unit across 44 NDCs.
Is generic cheaper than brand in the GLP-1 Receptor Agonist class?
Among products priced per ML, the average generic NADAC in this class is $59.7570, versus $438.4335 for brand — brand products average about 7.3× the generic price.
Which manufacturers make GLP-1 Receptor Agonist drugs?
9 manufacturers make drugs in the GLP-1 Receptor Agonist class. Ranked by number of NDCs, the largest are Eli Lilly and Company (16), Novo Nordisk (15), Teva Pharmaceuticals USA Inc. (3), AstraZeneca Pharmaceuticals LP (2), Hikma Pharmaceuticals USA Inc. (2).
How has GLP-1 Receptor Agonist pricing changed recently?
Over the past 7 days, 24 NDCs in this class rose and 13 fell, with a class-wide average change of -0.8%.